Direct-Acting Antivirals against Hepatitis C
Current Issues and Future Perspectives
- 1st Edition - April 13, 2026
- Latest edition
- Editor: Mohamed Mahmoud Zakaria El-Kassas
- Language: English
Direct-Acting Antivirals against Hepatitis C: Current Issues and Future Perspectives is a comprehensive reference that explores Chronic Hepatitis C management. This author… Read more
Description
Description
Direct-Acting Antivirals against Hepatitis C: Current Issues and Future Perspectives is a comprehensive and indispensable resource for anyone involved in the management of Chronic Hepatitis C. With its in-depth exploration of DAAs, from their molecular mechanisms to their clinical applications and future directions, this book equips clinicians, researchers, and students with the knowledge and insights needed to enhance their practices and contribute to the global fight against HCV infection.
Key features
Key features
- Provides the latest scientific analyses and discussions on Direct-Acting Antivirals (DAAs) for hepatitis C virus (HCV) treatment to explain the molecular mechanisms, therapeutic effectiveness, and advancements in CHC management
- Includes insights from leading experts in hepatology, virology, pharmacology, and immunology for comprehensive view of current HCV research and therapy, emerging strategies, and technologies
- Shares strategic insights to optimize DAA therapy to overcome challenges like resistance development, managing specific patient populations, and combining DAAs with other treatments
Readership
Readership
Table of contents
Table of contents
SECTION I: Direct acting antivirals (DAAs) in hepatitis C
1. Hepatitis C virus: OverviewMohamed Elbadry, Noha Eltaweel
2. HCV-host interactions: Virus specific factors, virus host related determinants, and intracellular signaling
James Palmer, Shahrzad Javadi, Stella Yao, Shymaa E. Bilasy, Ahmed El-Shamy
3. Introduction to direct-acting antivirals: Mechanisms of action and different classes
Saira S. Khalid, Khalid A. Alswat
SECTION II: Therapeutic strategies and clinical applications of DAAs in managing HCV
4. Clinical efficacy of different DAAs regimensAsmaa Gomaa, Imam Waked
5. Safety and tolerability of different DAAs regimens
Khalid Al-Naaman, Siham Al-Sinani
6. Benefits of treating HCV by DAAs beyond virological response
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Mariana N. Rincón-Sánchez, Arnulfo E. Morales-Galicia
7. Current landscape and guidelines of DAAs treatment in general population
Nikolaos Papadopoulos, George Papatheodoridis
8. Individualized treatment approaches in various special patient populations
Amani M. Ali, Aya M. AbdelMagid, Ahmed Cordie, Gamal Esmat
SECTION III: Challenges and future directions in DAA therapy
9. Antiviral resistance in hepatitis C and DAA therapyJackline Wangu Ngari, Ahmed Tawheed, Jin Zhong
10. DAA therapy and hepatocellular carcinoma
Loey Lung-Yi Mak, Vincent Wai-Sun Wong
11. Limitations and unmet needs in DAAs therapy
Aisha Elsharkawy, Rasha Eletreby
12. Emerging therapeutic strategies and future directions
Ahmed Saati, Faisal M. Sanai
13. Access to DAA therapy, and the role of DAAs in targeted HCV elimination
Elena Vargas-Accarino, Rafael Esteban, María Buti
Product details
Product details
- Edition: 1
- Latest edition
- Published: April 13, 2026
- Language: English
About the editor
About the editor
ME
Mohamed Mahmoud Zakaria El-Kassas
Mohamed El-Kassas, a distinguished figure in hepatology, held prestigious positions in global medical organizations such as IASL, AHPBCC, WGO, Global NASH Council, and SLMENA. He has also held administrative roles in EARTH and the Egyptian National Committee for the Control of Viral Hepatitis. With a PG Diploma in Clinical Research, he received awards and recognition for his research, including the Best Arab Researcher Prize in Natural Sciences. He has published over 200 peer-reviewed manuscripts and served on the editorial boards of journals like PLOS One, Frontiers, and JCTH. He also reviewed for over 70 international journals, contributing to the field of hepatology.